IQVIA (IQV) said Friday it formed a collaboration with SCRI Development Innovations, the contract research organization arm of Sarah Cannon Research Institute,, with the aim of accelerating the development of oncology trials for pharmaceutical and biotech partners worldwide.
Financial terms were not disclosed.
Under the collaboration, the two companies will seek to streamline cancer drug trials by enhancing clinical trial processes, remove operational hurdles, and expedite data delivery, the company said.
Shares were 0.6% higher in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。